Mabvax Therapeutics Holdings Inc Share Price Nasdaq
Equities
US87959M2089
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- USD | - |
2020 | MabVax Therapeutics Holdings, Inc. Went Out of Business | CI |
2020 | Second Amended Liquidation Plan & Disclosure Statment Approved for MabVax Therapeutics Holdings, Inc. | CI |
Sales 2016 | 148K 11.65M | Sales 2017 | - | Capitalization | 14.41M 1.13B |
---|---|---|---|---|---|
Net income 2016 | -17M -1.34B | Net income 2017 | -19M -1.5B | EV / Sales 2016 | 147 x |
Net Debt 2016 | 470K 37M | Net Debt 2017 | 2.48M 195M | EV / Sales 2017 | - |
P/E ratio 2016 |
-0.93
x | P/E ratio 2017 |
-0.25
x | Employees | - |
Yield 2016 * |
-
| Yield 2017 |
-
| Free-Float | 92.02% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 72 | - | |
Chief Tech/Sci/R&D Officer | 81 | 07/07/14 | |
Paul W. Maffuid
CTO | Chief Tech/Sci/R&D Officer | 68 | 07/07/14 |
Members of the board | Title | Age | Since |
---|---|---|---|
Chief Tech/Sci/R&D Officer | 81 | 07/07/14 |
1st Jan change | Capi. | |
---|---|---|
+9.58% | 115B | |
+12.41% | 106B | |
-2.59% | 21.96B | |
-12.38% | 21.87B | |
-5.29% | 19.21B | |
-3.35% | 18.08B | |
-38.57% | 17.71B | |
+7.51% | 14.32B | |
+35.67% | 12.42B |